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I read with interest the paper by Wei et al. [1], published
recently in the Journal of Thrombosis and Thrombolysis on
the assessment of the validity of the INR system for
patients with liver disease and wish to make comments.
The authors measured the INR with different commercial
thromboplastins for a cohort of patients with liver disease
and a cohort of patients stabilized on vitamin K antagonists
(VKA). While the between-thromboplastin INRs for the
patients with liver disease were significantly different,
those for the patients on VKA were not. The obvious
conclusion is that the INR (as it is calibrated for patients on
VKA and here called INRvka) is not valid for patients with
liver disease and, therefore, the model of end stage liver
disease (MELD) score, once proposed as an objective
index to prioritize patients for liver transplantation, would
not allow parity of organ allocation. In their discussion Wei
et al. [1], ignored at least seven of the many papers pub-
lished over the last few years on this topic. Here few
examples. Trotter et al. [2], were among the first in 2004 to
show that the MELD score was not effective in securing
parity of organ allocation. Other papers have consistently
shown (from 1994 to 1999) that the INR, devised for
patients on VKA, is not valid for patients with chronic liver
disease [3, 4]. In 2007, Tripodi et al. [5] and Bellest et al.
[6] reported independently on the same issue of Hepatol-
ogy that the INRvka is not valid for patients with chronic
liver disease as shown by the fact that the MELD, calcu-
lated by including in the equation the INRvka, depends on
the thromboplastin used for testing. In the same papers
these authors have independently shown that an alternative
system of ISI calibration, provisionally called ISIliver (as
opposed to the ISIvka) [5] can be obtained by inserting into
the calibration plot, plasmas from patients with chronic
liver disease instead of plasmas from patients on VKA [5,
6]. This alternative system of calibration proved effective
in minimizing between-thromboplastin MELD results.
More recently, Sermon et al. [7], confirmed these results,
and Tripodi et al. [8] extended this model of ISIliver cal-
ibration to portable coagulation monitors. Finally, a review
article on this topic has been published in the Journal of
Thrombosis and Haemostasis in 2009 [9] and official rec-
ommendations have been issued independently by the
International Society on Thrombosis and Haemostasis [10]
and by the American Journal of Transplantation [11].
Surprisingly, some of the above papers [2–6, 8, 9] that
appeared in the literature well before the publication of
Wei et al. [1] have escaped their attention.
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